Legand Biotech (LEGN) Thesis Intact Despite LB1901 Trial Termination - BMO
Tweet Send to a Friend
BMO Capital analyst Kostas Biliouris reiterated an Outperform rating and $77.00 price target on Legand Biotech Corp. (NASDAQ: LEGN) following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
